Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track LLY with free AI briefings, catalyst countdowns, and dilution alerts.

LLY · Eli Lilly and Company

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$4.9B Cash on Hand
CF+ Cash Runway
0.8% Short Interest
$1468.57 Analyst Target (29)
Follow LLY by email Get an email when LLY reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about LLY, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Tirzepatide
FDA approved May 2022 · Mounjaro
Type 2 Diabetes Phase 4 · NCT05433584 Active not recruiting
Dulaglutide
FDA approved Sep 2014 · Trulicity
Diabetes Mellitus, Type 2 Phase 3 · NCT07668336 Recruiting
Orforglipron
FDA approved Apr 2026 · Foundayo
Diabetes Mellitus, Type 2 Phase 3 · NCT07668336 Recruiting
Ramucirumab
FDA approved Apr 2014 · Cyramza
Gastric Cancer Phase 2/3 · NCT05002127 Completed
Abemaciclib
FDA approved Sep 2017 · Verzenio
Breast Neoplasms Phase 2 · NCT07935317 Not yet recruiting
Baricitinib
FDA approved May 2018 · Olumiant
HIV Infection Phase 2 · NCT07209267 Not yet recruiting
Imlunestrant
FDA approved Sep 2025 · Inluriyo
Healthy Phase 1 · NCT07918859 Not yet recruiting
Idelalisib Chronic Lymphocytic Leukemia Phase 4 · NCT07218341 Recruiting
Antihyperglycemic medication Type 2 Diabetes Phase 4 · NCT05433584 Active not recruiting
Pirtobrutinib Chronic Lymphocytic Leukemia Phase 4 · NCT07218341 Recruiting
Evorpacept Gastric Cancer Phase 2/3 · NCT05002127 Completed
Fluorouracil Neoplasms Phase 3 · NCT04607421 Active not recruiting
LY3650150 Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Phase 3 · NCT06338995 Recruiting
Eloralintide Obesity Phase 3 · NCT07881432 Not yet recruiting
Retatrutide Obesity Phase 3 · NCT07232719 Active not recruiting
Irinotecan Neoplasms Phase 3 · NCT04607421 Active not recruiting

Also used in these trials (approved or third-party drugs, not LLY's own candidates): Cetuximab, Encorafenib, Oxaliplatin, Paclitaxel, Capecitabine, Bevacizumab, Trastuzumab, Leucovorin, Obinutuzumab, Venetoclax, Anastrozole, Exemestane.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

LLY holds $4.9B in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when LLY files for a raise →

👥 Who Owns LLY

Insiders 9.8% Other 5%+ holders 0.7% Institutions (5941 holders) 85.7% Public and other holders 3.8%
HolderTypeShares% of sharesAs of
LILLY ENDOWMENT INC
Former 10% Shareholder
Insider 90,066,978 9.57% 2026-09-30
Blackrock Inc. Institution (13F) 67,936,153 7.22% 2026-09-30
Vanguard Capital Management Institution (13G, 5%+) 61,295,605 6.52% 2026-03-31
PNC Financial Services Group, Inc. Institution (13F) 51,295,197 5.45% 2026-09-30
State Street Corporation Institution (13F) 36,848,565 3.92% 2026-09-30
FMR, LLC Institution (13F) 29,959,147 3.18% 2026-09-30
Vanguard Portfolio Management LLC Institution (13F) 20,999,744 2.23% 2026-09-30
Geode Capital Management, LLC Institution (13F) 20,556,572 2.19% 2026-09-30
Capital Research Global Investors Institution (13F) 16,998,595 1.81% 2026-09-30
Morgan Stanley Institution (13F) 16,377,649 1.74% 2026-09-30
Eli Lilly and Company 5%+ holder (13D) 6,344,114 0.67% 2026-01-12
LILLY & Co ELI
10% owner
Insider 1,104,558 0.12% 2026-10-22

Share count 940,745,031 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-11-10
filed 2026-11-10
Jonsson Patrik
Gift (G) 704 – 53,443
2026-11-03
filed 2026-11-04
Ricks David A
Gift (G) 23,538 – 555,278
2026-11-02
filed 2026-11-03
Skovronsky Daniel
Gift (G) 119 – 159,953
2026-11-02
filed 2026-11-03
Hakim Anat
Sale (S) 5,000 $1,402.52 4,137
2026-11-01
filed 2026-11-03
Custer Kenneth L.
Option exercise (M) 3,220 – 13,361

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full LLY picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for LLY and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.